BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a research report sent to investors on Thursday morning.
CBPO has been the topic of several other reports. ValuEngine raised shares of China Biologic Products from a sell rating to a hold rating in a research note on Tuesday, July 10th. Zacks Investment Research lowered shares of China Biologic Products from a hold rating to a strong sell rating in a research note on Thursday, August 9th. Finally, Credit Suisse Group lowered shares of China Biologic Products from an outperform rating to a neutral rating in a research note on Monday, August 6th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $101.00.
Shares of CBPO stock traded down $0.64 during mid-day trading on Thursday, hitting $69.14. 217,913 shares of the stock were exchanged, compared to its average volume of 320,809. China Biologic Products has a 52-week low of $60.08 and a 52-week high of $107.44. The firm has a market cap of $2.29 billion, a P/E ratio of 16.31, a PEG ratio of 1.43 and a beta of 1.40.
China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.13). China Biologic Products had a return on equity of 13.53% and a net margin of 15.50%. The firm had revenue of $119.10 million for the quarter, compared to analysts’ expectations of $122.00 million. During the same period in the previous year, the company earned $1.32 earnings per share. The company’s revenue was up 19.6% compared to the same quarter last year. On average, research analysts expect that China Biologic Products will post 3.71 EPS for the current year.
A number of institutional investors have recently modified their holdings of CBPO. Bank of America Corp DE lifted its stake in China Biologic Products by 19.8% in the 2nd quarter. Bank of America Corp DE now owns 651,261 shares of the biopharmaceutical company’s stock valued at $64,690,000 after buying an additional 107,573 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in China Biologic Products in the 2nd quarter valued at about $10,310,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in China Biologic Products in the 2nd quarter valued at about $3,906,000. First Trust Advisors LP purchased a new position in China Biologic Products in the 2nd quarter valued at about $3,213,000. Finally, Northern Trust Corp lifted its stake in China Biologic Products by 339.3% in the 2nd quarter. Northern Trust Corp now owns 36,000 shares of the biopharmaceutical company’s stock valued at $3,576,000 after buying an additional 27,806 shares in the last quarter. 44.15% of the stock is currently owned by hedge funds and other institutional investors.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.